Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
3827 | 1826 | 42.1 | 92% |
Classes in level above (level 2) |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | CD28 | Author keyword | 39 | 23% | 8% | 151 |
2 | CD80 | Author keyword | 38 | 32% | 5% | 99 |
3 | B7 | Author keyword | 34 | 39% | 4% | 67 |
4 | B7 1 | Author keyword | 24 | 39% | 3% | 47 |
5 | CD86 | Author keyword | 21 | 25% | 4% | 74 |
6 | COSTIMULATION | Author keyword | 21 | 14% | 8% | 143 |
7 | B71 CD80 | Author keyword | 17 | 100% | 0% | 8 |
8 | B7 2 | Author keyword | 16 | 44% | 1% | 27 |
9 | CTLA4IG | Author keyword | 11 | 37% | 1% | 24 |
10 | CO STIMULATION | Author keyword | 10 | 17% | 3% | 58 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | CD28 | 39 | 23% | 8% | 151 | Search CD28 | Search CD28 |
2 | CD80 | 38 | 32% | 5% | 99 | Search CD80 | Search CD80 |
3 | B7 | 34 | 39% | 4% | 67 | Search B7 | Search B7 |
4 | B7 1 | 24 | 39% | 3% | 47 | Search B7+1 | Search B7+1 |
5 | CD86 | 21 | 25% | 4% | 74 | Search CD86 | Search CD86 |
6 | COSTIMULATION | 21 | 14% | 8% | 143 | Search COSTIMULATION | Search COSTIMULATION |
7 | B71 CD80 | 17 | 100% | 0% | 8 | Search B71+CD80 | Search B71+CD80 |
8 | B7 2 | 16 | 44% | 1% | 27 | Search B7+2 | Search B7+2 |
9 | CTLA4IG | 11 | 37% | 1% | 24 | Search CTLA4IG | Search CTLA4IG |
10 | CO STIMULATION | 10 | 17% | 3% | 58 | Search CO+STIMULATION | Search CO+STIMULATION |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | CD28 | 137 | 28% | 23% | 416 |
2 | CTLA 4 | 127 | 29% | 21% | 375 |
3 | CTLA 4 COUNTER RECEPTOR | 81 | 59% | 5% | 91 |
4 | ACTIVATION ANTIGEN B7 | 68 | 70% | 3% | 57 |
5 | COSTIMULATORY SIGNAL | 46 | 37% | 6% | 101 |
6 | CD28 DEFICIENT MICE | 42 | 39% | 5% | 85 |
7 | COSTIMULATION | 40 | 15% | 14% | 251 |
8 | ADDITIONAL LIGAND | 32 | 85% | 1% | 17 |
9 | B7 1 | 31 | 33% | 4% | 79 |
10 | B7 | 31 | 42% | 3% | 57 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
CD28/B7 system of T cell costimulation | 1996 | 1852 | 108 | 81% |
Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation | 2001 | 690 | 155 | 39% |
CD28/B7 costimulation: A review | 1998 | 291 | 223 | 58% |
THE B7 AND CD28 RECEPTOR FAMILIES | 1994 | 1214 | 87 | 70% |
CD28-mediated co-stimulation: A quantitative support for TCR signalling | 2003 | 272 | 147 | 32% |
The clinical utility of inhibiting CD28-mediated costimulation | 2009 | 71 | 86 | 35% |
The role of B7 costimulation in T-cell immunity | 1999 | 94 | 95 | 83% |
The role of B7 co-stimulation in activation and differentiation of CD4(+) and CD8(+) T cells | 1998 | 172 | 92 | 50% |
Co-stimulation in T cell responses | 1997 | 314 | 75 | 36% |
DISTINCT ROLES FOR THE COSTIMULATORY LIGANDS B7-1 AND B7-2 IN T-HELPER CELL-DIFFERENTIATION | 1995 | 333 | 21 | 81% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | CLIN SCI K4 414 | 2 | 67% | 0.1% | 2 |
2 | GRP GENE THER Y TUMORS | 2 | 67% | 0.1% | 2 |
3 | SECT IMMUNOPATHOGENESIS | 1 | 19% | 0.4% | 7 |
4 | AOR 11 | 1 | 100% | 0.1% | 2 |
5 | ARTHRIT IMMUNOL SECT 111R | 1 | 100% | 0.1% | 2 |
6 | CHAIR P PHYSIOL | 1 | 100% | 0.1% | 2 |
7 | SECT TUMOUR IMMUNOL | 1 | 40% | 0.1% | 2 |
8 | UNITA IMMUNOCHIM | 1 | 33% | 0.1% | 2 |
9 | AZN | 1 | 50% | 0.1% | 1 |
10 | DIAGNOST EXPT THER Y PROGRAMME | 1 | 50% | 0.1% | 1 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000254637 | ICOS//B7RP 1//ICOSL |
2 | 0.0000231261 | CTLA 4//IPILIMUMAB//CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 |
3 | 0.0000183510 | SECRETION INHIBITION//RNF13//PROTEASE ASSOCIATED DOMAIN |
4 | 0.0000097862 | ADV CELL MOL THER Y//SHUNDE PEOPLES HOSP//TUMOR VACCINE |
5 | 0.0000097776 | COSTIMULATION BLOCKADE//EMORY TRANSPLANT//MIXED CHIMERISM |
6 | 0.0000095177 | MULTI ORGAN TRANSPLANTAT PROGRAM//TROGOCYTOSIS//CLINICIAN SCIENTIST TRAINING PROGRAM |
7 | 0.0000092442 | T11TS//CD2//CD58 |
8 | 0.0000078134 | 4 1BB//OX40//CD137 |
9 | 0.0000065900 | MICROSURG GRP//CYTOL HISTOL MICROSCOP ANAT//DISULFIDE LINKED |
10 | 0.0000062991 | CANCER BIOTHERAPY//IST TIPIZZAZ TISSUTALE PROBLEMI DIALISI//INTRACELLULAR IMMUNOFLUORESCENCE |